New Prognostic and Predictive Markers in Cancer Progression
Costantini, Susan
New Prognostic and Predictive Markers in Cancer Progression - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021 - 1 electronic resource (294 p.)
Open Access
Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient's outcome and cancer recurrence probability after initial interventions such as surgery or drug treatments and, hence, to select follow-up and further treatment strategies. On the other hand, predictive markers are increasingly being used to evaluate the probability of benefit from clinical intervention(s), driving personalized medicine. Evolving technologies and the increasing availability of "multiomics" data are leading to the selection of numerous potential biomarkers, based on DNA, RNA, miRNA, protein, and metabolic alterations within cancer cells or tumor microenvironment, that may be combined with clinical and pathological data to greatly improve the prediction of both cancer progression and therapeutic treatment responses. However, in recent years, few biomarkers have progressed from discovery to become validated tools to be used in clinical practice. This Special Issue comprises eight review articles and five original studies on novel potential prognostic and predictive markers for different cancer types.
Creative Commons
English
books978-3-03943-978-2 9783039439775 9783039439782
10.3390/books978-3-03943-978-2 doi
Medicine
MSI2 OSCC oral cancer musashi 2 prognosis N-cadherin EMT breast cancer new metastasis eribulin blood biomarker bladder cancer immune checkpoint inhibitor CD8+ T effector cells microRNA biomarkers head and neck cancer laryngeal cancer prediction metastasis lifestyle habit chemo-/radio resistance therapeutic target AKT AR castration-resistant prostate cancer (CRPC) MAPK mTOR PI3K prostate cancer therapeutic resistance WNT miRNA melanoma melanoma resistance to MAPK/MEK inhibitors resistance to immune checkpoint inhibitors TNBC BRCA1/2 HRR PDL1 TILs PI3KCA PTEN CTCs CSC pancreatic cancer K-RAS oncogene oncogene dependency targeted therapies genomic mutations transcriptomics metabolomics selenoproteins cancer HUB nodes major histocompatibility complex (MHC) human leukocyte antigen (HLA) antigen processing machinery (APM) molecules carcinogenesis tumor predisposition cancer immunotherapy pheochromocytoma paraganglioma head and neck neoplasms head and neck tumors genetic syndromes mutations hyperglycemia cardioncology nivolumab cytokines cardiotoxicity acetyltransferase cancer prognosis NAA10 n/a
New Prognostic and Predictive Markers in Cancer Progression - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021 - 1 electronic resource (294 p.)
Open Access
Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient's outcome and cancer recurrence probability after initial interventions such as surgery or drug treatments and, hence, to select follow-up and further treatment strategies. On the other hand, predictive markers are increasingly being used to evaluate the probability of benefit from clinical intervention(s), driving personalized medicine. Evolving technologies and the increasing availability of "multiomics" data are leading to the selection of numerous potential biomarkers, based on DNA, RNA, miRNA, protein, and metabolic alterations within cancer cells or tumor microenvironment, that may be combined with clinical and pathological data to greatly improve the prediction of both cancer progression and therapeutic treatment responses. However, in recent years, few biomarkers have progressed from discovery to become validated tools to be used in clinical practice. This Special Issue comprises eight review articles and five original studies on novel potential prognostic and predictive markers for different cancer types.
Creative Commons
English
books978-3-03943-978-2 9783039439775 9783039439782
10.3390/books978-3-03943-978-2 doi
Medicine
MSI2 OSCC oral cancer musashi 2 prognosis N-cadherin EMT breast cancer new metastasis eribulin blood biomarker bladder cancer immune checkpoint inhibitor CD8+ T effector cells microRNA biomarkers head and neck cancer laryngeal cancer prediction metastasis lifestyle habit chemo-/radio resistance therapeutic target AKT AR castration-resistant prostate cancer (CRPC) MAPK mTOR PI3K prostate cancer therapeutic resistance WNT miRNA melanoma melanoma resistance to MAPK/MEK inhibitors resistance to immune checkpoint inhibitors TNBC BRCA1/2 HRR PDL1 TILs PI3KCA PTEN CTCs CSC pancreatic cancer K-RAS oncogene oncogene dependency targeted therapies genomic mutations transcriptomics metabolomics selenoproteins cancer HUB nodes major histocompatibility complex (MHC) human leukocyte antigen (HLA) antigen processing machinery (APM) molecules carcinogenesis tumor predisposition cancer immunotherapy pheochromocytoma paraganglioma head and neck neoplasms head and neck tumors genetic syndromes mutations hyperglycemia cardioncology nivolumab cytokines cardiotoxicity acetyltransferase cancer prognosis NAA10 n/a